Company intelligence / Profile preview

Cell Genesis

Seoul, Seoul, South Korea

Ownership: Private
Employees: ~50
Development stage: Other

Overview

CellGenesis is a South Korean biotechnology company specializing in the development and contract manufacturing of cell and gene therapies (CGT). The company operates as a specialized CDMO, providing end-to-end services from process development to GMP manufacturing for advanced therapy medicinal products. Their proprietary technology platforms focus on enhancing the efficacy and scalability of stem cell and immune cell therapies, including NK cell-based treatments. CellGenesis aims to bridge the gap between early-stage research and commercial production for global biopharmaceutical partners.

Therapeutic areas: OncologyNeurology
Modalities: Cell therapyGene therapyStem cell therapyNK cell therapy
Industry: Biotech

Partnerships

GC CellSartorius

Beyond the preview

Go deeper on Cell Genesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell Genesis.

Explore the full profile